We're very sorry

Wir sind sehr traurig
Nous sommes très désolés
Siamo molto spiacenti
Estamos muy apesadumbrados
私達は非常に残念である
我们非常抱歉
我們非常抱歉
우리는 아주 유감스럽다
Мы очень огорченны
Nós somos muito pesarosos

The page you requested cannot be found

Alpha-1 Therapy
United States
Search    
Include All CSL Behring Country Sites

Alpha-1 Therapy

Alpha-1 deficiency is a genetic condition caused by a lack of alpha1 antitrypsin, a protein that protects the lungs from an enzyme called neutrophil elastase. The primary function of neutrophil elastase is to rid the lungs from germs and old or damaged cells. However, if it is not properly regulated, neutrophil elastase can attack healthy lung tissue and cause damage.

Most people who do not make enough alpha1 antitrypsin have a condition known as Alpha-1 and are susceptible to lung disease.

Alpha-1-associated emphysema can become chronic and weaken your lungs.

For more information, please see these CSL Behring resources:

www.CSLcareZ.com
www.Zemaira.com

Important Safety Information for Zemaira

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A1-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.


CRP16-05-0001 05/2016
© 2017 CSL Behring